Payment overview · 2025
General Payments
$2,418.38
100 reported records · 16 companies
Healthcare provider profile · identity verified
Fadi E Damouni, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MILLSBORO, DE · NPI 1245295260
Verified facts
What the public records show
CMS Open Payments records show Fadi E Damouni, MD received $2,418.38 in general payments during 2025 across 100 reported records.
Corcept Therapeutics accounted for 29.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Paxlovid, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 207 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $720.39 | 29.8% | 21 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $562.15 | 23.2% | 21 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $399.59 | 16.5% | 19 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $173.52 | 7.2% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $126.66 | 5.2% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $91.17 | 3.8% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $84.27 | 3.5% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $76.86 | 3.2% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $49.90 | 2.1% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.58 | 1.4% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.33 | 0.8% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $19.09 | 0.8% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $17.65 | 0.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.92 | 0.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.33 | 0.6% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $13.97 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,418.38 | 100 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $720.39 | 21 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $324.10 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $226.38 | 11 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $195.17 | 7 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $194.98 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $126.66 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $100.77 | 5 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $91.17 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $88.33 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $84.46 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $84.27 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $84.27 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $76.86 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $76.86 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $72.75 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $72.75 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $49.90 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $32.58 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $19.33 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $19.09 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $17.65 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $15.92 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.33 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $13.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 65 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 109 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 207 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 19 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 64 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
92 | 27 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
65 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
109 | 39 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
64 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
109 | 39 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
207 | 50 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
157 | 50 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1317 | 432 |
| Amlodipine Besylate | Amlodipine Besylate | 892 | 290 |
| Omeprazole | Omeprazole | 737 | 250 |
| Levothyroxine Sodium | Levothyroxine Sodium | 633 | 182 |
| Lisinopril | Lisinopril | 615 | 203 |
| Losartan Potassium | Losartan Potassium | 555 | 182 |
| Gabapentin | Gabapentin | 432 | 159 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 402 | 144 |
| Metoprolol Succinate | Metoprolol Succinate | 396 | 131 |
| Metformin Hcl | Metformin Hcl | 385 | 119 |
| Pantoprazole Sodium | Pantoprazole Sodium | 355 | 106 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 351 | 144 |
| Furosemide | Furosemide | 314 | 107 |
| Hydrochlorothiazide | Hydrochlorothiazide | 314 | 101 |
| Tamsulosin Hcl | Tamsulosin Hcl | 291 | 85 |
| Pravastatin Sodium | Pravastatin Sodium | 283 | 92 |
| Simvastatin | Simvastatin | 276 | 84 |
| Montelukast Sodium | Montelukast Sodium | 247 | 70 |
| Ezetimibe | Ezetimibe | 243 | 79 |
| Escitalopram Oxalate | Escitalopram Oxalate | 239 | 79 |
| Hydralazine Hcl | Hydralazine Hcl | 234 | 71 |
| Famotidine | Famotidine | 210 | 73 |
| Ozempic | Semaglutide | 207 | 50 |
| Fluticasone Propionate | Fluticasone Propionate | 205 | 90 |
| Metoprolol Tartrate | Metoprolol Tartrate | 203 | 67 |
| Potassium Chloride | Potassium Chloride | 177 | 54 |
| Metformin Hcl Er | Metformin Hcl | 175 | 59 |
| Sertraline Hcl | Sertraline Hcl | 174 | 54 |
| Eliquis | Apixaban | 157 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 151 | 44 |
| Allopurinol | Allopurinol | 146 | 50 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 135 | 46 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 132 | 46 |
| Carvedilol | Carvedilol | 129 | 45 |
| Atenolol | Atenolol | 127 | 34 |
| Spironolactone | Spironolactone | 124 | 42 |
| Fenofibrate | Fenofibrate Nanocrystallized | 122 | 36 |
| Buspirone Hcl | Buspirone Hcl | 116 | 36 |
| Jardiance | Empagliflozin | 109 | 39 |
| Trazodone Hcl | Trazodone Hcl | 109 | 42 |
| Prednisone | Prednisone | 93 | 71 |
| Synthroid | Levothyroxine Sodium | 92 | 27 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 90 | 79 |
| Doxazosin Mesylate | Doxazosin Mesylate | 87 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 86 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 86 | 27 |
| Finasteride | Finasteride | 76 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 75 | 37 |
| Bupropion Xl | Bupropion Hcl | 74 | 22 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 73 | 27 |
| Meloxicam | Meloxicam | 67 | 46 |
| Alendronate Sodium | Alendronate Sodium | 66 | 25 |
| Nebivolol Hcl | Nebivolol Hcl | 66 | 24 |
| Farxiga | Dapagliflozin Propanediol | 65 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 65 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 64 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 63 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 63 | 23 |
| Tramadol Hcl | Tramadol Hcl | 63 | 26 |
| Baclofen | Baclofen | 61 | 20 |
| Glipizide | Glipizide | 61 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 61 | 18 |
| Terazosin Hcl | Terazosin Hcl | 61 | 18 |
| Xarelto | Rivaroxaban | 60 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | 20 |
| Glimepiride | Glimepiride | 56 | 14 |
| Methylprednisolone | Methylprednisolone | 56 | 49 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 56 | 29 |
| Lorazepam | Lorazepam | 55 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 54 | 27 |
| Meclizine Hcl | Meclizine Hcl | 53 | 32 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | 14 |
| Glipizide Er | Glipizide | 46 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 44 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 43 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 35 |
| Nystatin | Nystatin | 42 | 26 |
| Alprazolam | Alprazolam | 40 | 17 |
| Azithromycin | Azithromycin | 39 | 37 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 39 | 11 |
| Levetiracetam | Levetiracetam | 39 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 38 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 37 | suppressed |
| Gemfibrozil | Gemfibrozil | 37 | 12 |
| Propranolol Hcl | Propranolol Hcl | 37 | suppressed |
| Ramipril | Ramipril | 37 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Clonazepam | Clonazepam | 36 | suppressed |
| Nifedipine Er | Nifedipine | 36 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 36 | suppressed |
| Myrbetriq | Mirabegron | 35 | suppressed |
| Cephalexin | Cephalexin | 34 | 26 |
| Mirtazapine | Mirtazapine | 34 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 19 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | 11 |
| Lansoprazole | Lansoprazole | 32 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | 12 |
| Valsartan | Valsartan | 32 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 25 |
| Linzess | Linaclotide | 29 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | 11 |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Risperidone | Risperidone | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Irbesartan | Irbesartan | 27 | 11 |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 25 | 19 |
| Topiramate | Topiramate | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 22 |
| Celecoxib | Celecoxib | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Colchicine | Colchicine | 22 | 12 |
| Diazepam | Diazepam | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 21 | 14 |
| Pregabalin | Pregabalin | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | 12 |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | 11 |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Folic Acid | Folic Acid | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Niacin Er | Niacin | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 12 |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 13 | 11 |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Ssd | Silver Sulfadiazine | 13 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,418.38 · 100 records | Corcept Therapeutics | AIRSUPRA, BREZTRI, FARXIGA, FUROSCIX, GEMTESA, JARDIANCE, Kerendia, Korlym, MOUNJARO, NEXLETOL, OTEZLA, Ohtuvayre, Ozempic, PAXLOVID, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error